trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,lung02', 'lung', 'daiichi']
tomorrow at #esmo22: we will be sharing #latebreaking results from the destiny-lung02 phase 2 trial in patients with #her2 mutant metastatic non-small cell #lungcancer. 
We create life-changing solutions for patients. See our guidelines: https://t.co/4iEAbpw1Wx